Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

An enhanced expression of human epidermal growth factor receptor 2 (HER2, ErbB2) often occurs in an advanced stage of breast, ovarian, gastric or esophageal cancer, and pancreatic ductal adenocarcinoma (PDAC). Commonly, HER2 expression is associated with poor clinical outcome or chemoresistance in o...

Full description

Bibliographic Details
Main Authors: Hans H. Oberg, Christian Kellner, Daniel Gonnermann, Susanne Sebens, Dirk Bauerschlag, Martin Gramatzki, Dieter Kabelitz, Matthias Peipp, Daniela Wesch
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-04-01
Series:Frontiers in Immunology
Subjects:
human γδ T cells
human natural killer cells
human epidermal growth factor receptor 2
trastuzumab
bispecific antibody
tribody
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2018.00814/full

Internet

http://journal.frontiersin.org/article/10.3389/fimmu.2018.00814/full

Similar Items